PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital
Company appoints five new independent directors to reconstituted board
Company appoints five new independent directors to reconstituted board
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
The company has reported total income of Rs. 1.56 crores during the period ended June 30, 2022
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
The company has reported total income of Rs. 6276.54 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 129.96 crores during the period ended June 30, 2022.
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
Subscribe To Our Newsletter & Stay Updated